P01 A Service Evaluation of Implementation of RCPCH Brain Pathways Clinical Guideline Linked to HeadSmart – Be Brain Tumour Aware (HeadSmart). A Health Foundation, Closing the Gap Project
Aims To evaluate the impact of the HeadSmart Campaign upon symptom interval (SI) for newly diagnosed childhood brain tumours at UK Children’s Cancer and Leukaemia Group (CCLG) treatment centres. Introduction HeadSmart’s national awareness campaign (www.headsmart.org.uk) aims to disseminate the RCPCH...
Gespeichert in:
Veröffentlicht in: | Archives of disease in childhood 2013-06, Vol.98 (Suppl 1), p.A1-A1 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | A1 |
---|---|
container_issue | Suppl 1 |
container_start_page | A1 |
container_title | Archives of disease in childhood |
container_volume | 98 |
creator | Wilne, S Liu, J Clough, L Dudley, J Lakhanpaul, M Kennedy, C Lindsell, S Baker, M Trusler, J Carbury, P Grundy, R Walker, D |
description | Aims To evaluate the impact of the HeadSmart Campaign upon symptom interval (SI) for newly diagnosed childhood brain tumours at UK Children’s Cancer and Leukaemia Group (CCLG) treatment centres. Introduction HeadSmart’s national awareness campaign (www.headsmart.org.uk) aims to disseminate the RCPCH endorsed Brain Pathways Guideline for referral and imaging of patients with symptoms suggestive of brain tumour. Methods The SI experienced by children newly diagnosed with brain tumours was determined from January 2011 to December 2012 by HeadSmart Clinical Champions at 18 CCLG treatment centres reporting to an online database as part of a service evaluation under Caldicott guardian permission. Results Data from 353 children (median 6.7 yr, range 0.02–17.71) is available. The median SI is 7.57 weeks (mean 21.8, range 0 to 435 weeks). The median symptom onset to consultation with a healthcare professional interval is 2.3 weeks (mean 12.9, range 0 to 433 weeks), and the median consultation to diagnosis interval is 2.7 weeks (mean 9.0, range 0 to 156 weeks). Imaging that identified the tumour took place as an outpatient in 28.3%, an inpatient in 43.3% and from the emergency department in 19.5%. 3.1% of children were referred via a “two week wait” cancer referral. The most frequent symptoms and signs at symptom onset were headache (46%), vomiting (41%), abnormal coordination (12%), abnormal gait (12%), lethargy (12%); and at diagnosis were vomiting (53%), headache (48%), abnormal coordination (26%), abnormal gait (23%), lethargy (21%), and papilloedema (21%). The medium SI prior to campaign launch was 9.3 weeks, and after launch 6.9 weeks (p = 0.043); mean SI during the same period was 22.9 and 21.0 weeks. The median consultation to diagnosis interval was 3 weeks prior to launch; post launch it was 2.3 weeks during the first 6 months, and reduced to 1.0 week between the 7th – 18th month of the campaign (p = 0.026). Changes in mean during the same period did not show a reduction trend; mean SI 15.2, 10.3, 13.3 weeks, respectively. Conclusions Analysis of the SI experienced by UK children before and after the HeadSmart launch suggests that the SI and the consultation to diagnosis interval have reduced. Further data is required to determine whether this reduction is sustained. |
doi_str_mv | 10.1136/archdischild-2013-304107.001 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1828883487</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4214856391</sourcerecordid><originalsourceid>FETCH-LOGICAL-b2211-c9587febbe24252ccd2499f706d54f97c1c40c757634257c35ff080be35d92d43</originalsourceid><addsrcrecordid>eNqVkc1uEzEUhUcIJELhHSzBAiQm-G_GHolNOmqTSlGJSKnYWR7bQ5zOT2p7WrrrhifggXiXPkkdporYsrLu9Tk-1_dLkncIThEi-Sfp1EZbrza20SmGiKQEUgTZFEL0LJkgmvPYpvR5MoEQkrTgnL9MXnm_jQLMOZkkf1YQPdz_moG1cTdWGXByI5tBBtt3oK_BWbtrTGu6cOh8LVflAhw7aTuwkmFzK-88KBvbWSUbMB-sNrEwYGm7K6NB6MHCSL1upQvg4f43ODZP5ouh7QcHZrfSGfD-IPowBbO9pQkbcNoPnf6b_DFG9N52P0DYGDCXO7By_dao8Dp5UcvGmzdP51Hy7fTkolykyy_zs3K2TCuMEUpVkXFWm6oymOIMK6UxLYqawVxntC6YQopCxTKWk3jPFMnqGnJYGZLpAmtKjpK347s7118PxgexjdN3MVIgHlfJCeUsqj6PKuV6752pxc7Z-Ks7gaDYIxP_IhN7ZGJEJiKRaE9Hu_XB_Dx4pbsSOSMsE-eXpcBrnuXL75diPxQb9VW7_b-kR4IbsCw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1828883487</pqid></control><display><type>article</type><title>P01 A Service Evaluation of Implementation of RCPCH Brain Pathways Clinical Guideline Linked to HeadSmart – Be Brain Tumour Aware (HeadSmart). A Health Foundation, Closing the Gap Project</title><source>BMJ Journals - NESLi2</source><creator>Wilne, S ; Liu, J ; Clough, L ; Dudley, J ; Lakhanpaul, M ; Kennedy, C ; Lindsell, S ; Baker, M ; Trusler, J ; Carbury, P ; Grundy, R ; Walker, D</creator><creatorcontrib>Wilne, S ; Liu, J ; Clough, L ; Dudley, J ; Lakhanpaul, M ; Kennedy, C ; Lindsell, S ; Baker, M ; Trusler, J ; Carbury, P ; Grundy, R ; Walker, D</creatorcontrib><description>Aims To evaluate the impact of the HeadSmart Campaign upon symptom interval (SI) for newly diagnosed childhood brain tumours at UK Children’s Cancer and Leukaemia Group (CCLG) treatment centres. Introduction HeadSmart’s national awareness campaign (www.headsmart.org.uk) aims to disseminate the RCPCH endorsed Brain Pathways Guideline for referral and imaging of patients with symptoms suggestive of brain tumour. Methods The SI experienced by children newly diagnosed with brain tumours was determined from January 2011 to December 2012 by HeadSmart Clinical Champions at 18 CCLG treatment centres reporting to an online database as part of a service evaluation under Caldicott guardian permission. Results Data from 353 children (median 6.7 yr, range 0.02–17.71) is available. The median SI is 7.57 weeks (mean 21.8, range 0 to 435 weeks). The median symptom onset to consultation with a healthcare professional interval is 2.3 weeks (mean 12.9, range 0 to 433 weeks), and the median consultation to diagnosis interval is 2.7 weeks (mean 9.0, range 0 to 156 weeks). Imaging that identified the tumour took place as an outpatient in 28.3%, an inpatient in 43.3% and from the emergency department in 19.5%. 3.1% of children were referred via a “two week wait” cancer referral. The most frequent symptoms and signs at symptom onset were headache (46%), vomiting (41%), abnormal coordination (12%), abnormal gait (12%), lethargy (12%); and at diagnosis were vomiting (53%), headache (48%), abnormal coordination (26%), abnormal gait (23%), lethargy (21%), and papilloedema (21%). The medium SI prior to campaign launch was 9.3 weeks, and after launch 6.9 weeks (p = 0.043); mean SI during the same period was 22.9 and 21.0 weeks. The median consultation to diagnosis interval was 3 weeks prior to launch; post launch it was 2.3 weeks during the first 6 months, and reduced to 1.0 week between the 7th – 18th month of the campaign (p = 0.026). Changes in mean during the same period did not show a reduction trend; mean SI 15.2, 10.3, 13.3 weeks, respectively. Conclusions Analysis of the SI experienced by UK children before and after the HeadSmart launch suggests that the SI and the consultation to diagnosis interval have reduced. Further data is required to determine whether this reduction is sustained.</description><identifier>ISSN: 0003-9888</identifier><identifier>EISSN: 1468-2044</identifier><identifier>DOI: 10.1136/archdischild-2013-304107.001</identifier><identifier>CODEN: ADCHAK</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health</publisher><subject>Brain ; Brain tumors ; Emergency medical services ; Guidelines ; Leukemia ; Referral</subject><ispartof>Archives of disease in childhood, 2013-06, Vol.98 (Suppl 1), p.A1-A1</ispartof><rights>2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2013 (c) 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://adc.bmj.com/content/98/Suppl_1/A1.1.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://adc.bmj.com/content/98/Suppl_1/A1.1.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,780,784,3196,23571,27924,27925,77600,77631</link.rule.ids></links><search><creatorcontrib>Wilne, S</creatorcontrib><creatorcontrib>Liu, J</creatorcontrib><creatorcontrib>Clough, L</creatorcontrib><creatorcontrib>Dudley, J</creatorcontrib><creatorcontrib>Lakhanpaul, M</creatorcontrib><creatorcontrib>Kennedy, C</creatorcontrib><creatorcontrib>Lindsell, S</creatorcontrib><creatorcontrib>Baker, M</creatorcontrib><creatorcontrib>Trusler, J</creatorcontrib><creatorcontrib>Carbury, P</creatorcontrib><creatorcontrib>Grundy, R</creatorcontrib><creatorcontrib>Walker, D</creatorcontrib><title>P01 A Service Evaluation of Implementation of RCPCH Brain Pathways Clinical Guideline Linked to HeadSmart – Be Brain Tumour Aware (HeadSmart). A Health Foundation, Closing the Gap Project</title><title>Archives of disease in childhood</title><addtitle>Arch Dis Child</addtitle><description>Aims To evaluate the impact of the HeadSmart Campaign upon symptom interval (SI) for newly diagnosed childhood brain tumours at UK Children’s Cancer and Leukaemia Group (CCLG) treatment centres. Introduction HeadSmart’s national awareness campaign (www.headsmart.org.uk) aims to disseminate the RCPCH endorsed Brain Pathways Guideline for referral and imaging of patients with symptoms suggestive of brain tumour. Methods The SI experienced by children newly diagnosed with brain tumours was determined from January 2011 to December 2012 by HeadSmart Clinical Champions at 18 CCLG treatment centres reporting to an online database as part of a service evaluation under Caldicott guardian permission. Results Data from 353 children (median 6.7 yr, range 0.02–17.71) is available. The median SI is 7.57 weeks (mean 21.8, range 0 to 435 weeks). The median symptom onset to consultation with a healthcare professional interval is 2.3 weeks (mean 12.9, range 0 to 433 weeks), and the median consultation to diagnosis interval is 2.7 weeks (mean 9.0, range 0 to 156 weeks). Imaging that identified the tumour took place as an outpatient in 28.3%, an inpatient in 43.3% and from the emergency department in 19.5%. 3.1% of children were referred via a “two week wait” cancer referral. The most frequent symptoms and signs at symptom onset were headache (46%), vomiting (41%), abnormal coordination (12%), abnormal gait (12%), lethargy (12%); and at diagnosis were vomiting (53%), headache (48%), abnormal coordination (26%), abnormal gait (23%), lethargy (21%), and papilloedema (21%). The medium SI prior to campaign launch was 9.3 weeks, and after launch 6.9 weeks (p = 0.043); mean SI during the same period was 22.9 and 21.0 weeks. The median consultation to diagnosis interval was 3 weeks prior to launch; post launch it was 2.3 weeks during the first 6 months, and reduced to 1.0 week between the 7th – 18th month of the campaign (p = 0.026). Changes in mean during the same period did not show a reduction trend; mean SI 15.2, 10.3, 13.3 weeks, respectively. Conclusions Analysis of the SI experienced by UK children before and after the HeadSmart launch suggests that the SI and the consultation to diagnosis interval have reduced. Further data is required to determine whether this reduction is sustained.</description><subject>Brain</subject><subject>Brain tumors</subject><subject>Emergency medical services</subject><subject>Guidelines</subject><subject>Leukemia</subject><subject>Referral</subject><issn>0003-9888</issn><issn>1468-2044</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqVkc1uEzEUhUcIJELhHSzBAiQm-G_GHolNOmqTSlGJSKnYWR7bQ5zOT2p7WrrrhifggXiXPkkdporYsrLu9Tk-1_dLkncIThEi-Sfp1EZbrza20SmGiKQEUgTZFEL0LJkgmvPYpvR5MoEQkrTgnL9MXnm_jQLMOZkkf1YQPdz_moG1cTdWGXByI5tBBtt3oK_BWbtrTGu6cOh8LVflAhw7aTuwkmFzK-88KBvbWSUbMB-sNrEwYGm7K6NB6MHCSL1upQvg4f43ODZP5ouh7QcHZrfSGfD-IPowBbO9pQkbcNoPnf6b_DFG9N52P0DYGDCXO7By_dao8Dp5UcvGmzdP51Hy7fTkolykyy_zs3K2TCuMEUpVkXFWm6oymOIMK6UxLYqawVxntC6YQopCxTKWk3jPFMnqGnJYGZLpAmtKjpK347s7118PxgexjdN3MVIgHlfJCeUsqj6PKuV6752pxc7Z-Ks7gaDYIxP_IhN7ZGJEJiKRaE9Hu_XB_Dx4pbsSOSMsE-eXpcBrnuXL75diPxQb9VW7_b-kR4IbsCw</recordid><startdate>201306</startdate><enddate>201306</enddate><creator>Wilne, S</creator><creator>Liu, J</creator><creator>Clough, L</creator><creator>Dudley, J</creator><creator>Lakhanpaul, M</creator><creator>Kennedy, C</creator><creator>Lindsell, S</creator><creator>Baker, M</creator><creator>Trusler, J</creator><creator>Carbury, P</creator><creator>Grundy, R</creator><creator>Walker, D</creator><general>BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88B</scope><scope>88E</scope><scope>88I</scope><scope>8A4</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>CJNVE</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0P</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEDU</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>201306</creationdate><title>P01 A Service Evaluation of Implementation of RCPCH Brain Pathways Clinical Guideline Linked to HeadSmart – Be Brain Tumour Aware (HeadSmart). A Health Foundation, Closing the Gap Project</title><author>Wilne, S ; Liu, J ; Clough, L ; Dudley, J ; Lakhanpaul, M ; Kennedy, C ; Lindsell, S ; Baker, M ; Trusler, J ; Carbury, P ; Grundy, R ; Walker, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b2211-c9587febbe24252ccd2499f706d54f97c1c40c757634257c35ff080be35d92d43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Brain</topic><topic>Brain tumors</topic><topic>Emergency medical services</topic><topic>Guidelines</topic><topic>Leukemia</topic><topic>Referral</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wilne, S</creatorcontrib><creatorcontrib>Liu, J</creatorcontrib><creatorcontrib>Clough, L</creatorcontrib><creatorcontrib>Dudley, J</creatorcontrib><creatorcontrib>Lakhanpaul, M</creatorcontrib><creatorcontrib>Kennedy, C</creatorcontrib><creatorcontrib>Lindsell, S</creatorcontrib><creatorcontrib>Baker, M</creatorcontrib><creatorcontrib>Trusler, J</creatorcontrib><creatorcontrib>Carbury, P</creatorcontrib><creatorcontrib>Grundy, R</creatorcontrib><creatorcontrib>Walker, D</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Education Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>Education Periodicals</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Education Collection</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Education Database</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Education</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Archives of disease in childhood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wilne, S</au><au>Liu, J</au><au>Clough, L</au><au>Dudley, J</au><au>Lakhanpaul, M</au><au>Kennedy, C</au><au>Lindsell, S</au><au>Baker, M</au><au>Trusler, J</au><au>Carbury, P</au><au>Grundy, R</au><au>Walker, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P01 A Service Evaluation of Implementation of RCPCH Brain Pathways Clinical Guideline Linked to HeadSmart – Be Brain Tumour Aware (HeadSmart). A Health Foundation, Closing the Gap Project</atitle><jtitle>Archives of disease in childhood</jtitle><addtitle>Arch Dis Child</addtitle><date>2013-06</date><risdate>2013</risdate><volume>98</volume><issue>Suppl 1</issue><spage>A1</spage><epage>A1</epage><pages>A1-A1</pages><issn>0003-9888</issn><eissn>1468-2044</eissn><coden>ADCHAK</coden><abstract>Aims To evaluate the impact of the HeadSmart Campaign upon symptom interval (SI) for newly diagnosed childhood brain tumours at UK Children’s Cancer and Leukaemia Group (CCLG) treatment centres. Introduction HeadSmart’s national awareness campaign (www.headsmart.org.uk) aims to disseminate the RCPCH endorsed Brain Pathways Guideline for referral and imaging of patients with symptoms suggestive of brain tumour. Methods The SI experienced by children newly diagnosed with brain tumours was determined from January 2011 to December 2012 by HeadSmart Clinical Champions at 18 CCLG treatment centres reporting to an online database as part of a service evaluation under Caldicott guardian permission. Results Data from 353 children (median 6.7 yr, range 0.02–17.71) is available. The median SI is 7.57 weeks (mean 21.8, range 0 to 435 weeks). The median symptom onset to consultation with a healthcare professional interval is 2.3 weeks (mean 12.9, range 0 to 433 weeks), and the median consultation to diagnosis interval is 2.7 weeks (mean 9.0, range 0 to 156 weeks). Imaging that identified the tumour took place as an outpatient in 28.3%, an inpatient in 43.3% and from the emergency department in 19.5%. 3.1% of children were referred via a “two week wait” cancer referral. The most frequent symptoms and signs at symptom onset were headache (46%), vomiting (41%), abnormal coordination (12%), abnormal gait (12%), lethargy (12%); and at diagnosis were vomiting (53%), headache (48%), abnormal coordination (26%), abnormal gait (23%), lethargy (21%), and papilloedema (21%). The medium SI prior to campaign launch was 9.3 weeks, and after launch 6.9 weeks (p = 0.043); mean SI during the same period was 22.9 and 21.0 weeks. The median consultation to diagnosis interval was 3 weeks prior to launch; post launch it was 2.3 weeks during the first 6 months, and reduced to 1.0 week between the 7th – 18th month of the campaign (p = 0.026). Changes in mean during the same period did not show a reduction trend; mean SI 15.2, 10.3, 13.3 weeks, respectively. Conclusions Analysis of the SI experienced by UK children before and after the HeadSmart launch suggests that the SI and the consultation to diagnosis interval have reduced. Further data is required to determine whether this reduction is sustained.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health</pub><doi>10.1136/archdischild-2013-304107.001</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0003-9888 |
ispartof | Archives of disease in childhood, 2013-06, Vol.98 (Suppl 1), p.A1-A1 |
issn | 0003-9888 1468-2044 |
language | eng |
recordid | cdi_proquest_journals_1828883487 |
source | BMJ Journals - NESLi2 |
subjects | Brain Brain tumors Emergency medical services Guidelines Leukemia Referral |
title | P01 A Service Evaluation of Implementation of RCPCH Brain Pathways Clinical Guideline Linked to HeadSmart – Be Brain Tumour Aware (HeadSmart). A Health Foundation, Closing the Gap Project |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T07%3A10%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P01%E2%80%85A%20Service%20Evaluation%20of%20Implementation%20of%20RCPCH%20Brain%20Pathways%20Clinical%20Guideline%20Linked%20to%20HeadSmart%20%E2%80%93%20Be%20Brain%20Tumour%20Aware%20(HeadSmart).%20A%20Health%20Foundation,%20Closing%20the%20Gap%20Project&rft.jtitle=Archives%20of%20disease%20in%20childhood&rft.au=Wilne,%20S&rft.date=2013-06&rft.volume=98&rft.issue=Suppl%201&rft.spage=A1&rft.epage=A1&rft.pages=A1-A1&rft.issn=0003-9888&rft.eissn=1468-2044&rft.coden=ADCHAK&rft_id=info:doi/10.1136/archdischild-2013-304107.001&rft_dat=%3Cproquest_cross%3E4214856391%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1828883487&rft_id=info:pmid/&rfr_iscdi=true |